Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Purchase individual online access for 1 year to this journal.
Price: EUR 595.00Impact Factor 2024: 3.4
The Journal of Alzheimer’s Disease is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer’s disease.
The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research that will expedite our fundamental understanding of Alzheimer’s disease.
Authors: Pérez, Mar | Cuadros, Raquel | Benítez, María J. | Jiménez, Juan S.
Article Type: Research Article
Abstract: The interaction of amyloid β (Aβ) 25–35 with tau protein and with the peptide 1/2R (KVTSKCGSLGNIHHKPGGG), has been investigated by chromatography, electron microscopy, and surface plasmon resonance (SPR). Aβ 25–35 comprises the minimum region of Aβ peptide that is able to aggregate into fibrils, and 1/2R contains residues 307–325 from the tau region involved in microtubule binding. The results of chromatography showed that Aβ 25–35 induces the aggregation of tau protein and of tau peptide 1/2R. Likewise, the results of electron microscopy showed that Aβ 25–35 increases the tau peptide polymerization observed in the presence of polyanions like heparin. A …decrease in Aβ 25–35 aggregation induced by tau peptide was also observed by both techniques. No direct interaction between tau protein immobilized on the sensor surface and Aβ 25–35 could be detected by SPR. However, incubation of tau protein at room temperature produced the loss of capability of this protein for interacting with the active biosensor surface. The presence of Aβ 25–35 during the incubation of tau protein makes more efficient this loss of interacting capability with the sensor surface. These results clearly indicate that Aβ 25–35, the peptide region to which the cytotoxic properties of Aβ can be assigned, interacts with the peptide region of tau protein involved in microtubule binding. This interaction produces the aggregation of tau peptide and the concomitant disassembling of Aβ 25–35, offering thus an explanation to the lack of co-localization of neurofibrillary tangles and senile plaques in Alzheimer's disease, and suggesting the possibility that tau protein may have a protective action by preventing Aβ from adopting the cytotoxic, aggregated form. Show more
Keywords: Alzheimer's disease, tau protein, amyloid β 25–35, surface plasmon resonance
DOI: 10.3233/JAD-2004-6501
Citation: Journal of Alzheimer's Disease, vol. 6, no. 5, pp. 461-467, 2004
Authors: van Horssen, Jack | de Vos, Rob A.I. | Steur, Ernst N.H. Jansen | David, Guido | Wesseling, Pieter | de Waal, Robert M.W. | Verbeek, Marcel M.
Article Type: Research Article
Abstract: α-Synuclein is the major constituent of Lewy bodies and Lewy neurites in Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Relatively little is known about the exact mechanism of α-synuclein deposition and fibrillization in theseα-synucleinopathies. In order to better understand the pathogenesis of α-synucleinopathies it is important to identify molecules that regulate the fibrillization of α-synuclein. Since it has been demonstrated that heparan sulfate proteoglycans (HSPGs) and glycosaminoglycans (GAGs) promote the conversion of non-fibrillar amyloid β-protein (Aβ) into neurotoxic fibrillar Aβ in Alzheimer's disease, they might also be involved in α-synuclein aggregation. It was the aim of our study …to examine the distribution pattern of these macromolecules in PD brains and the possible association with Lewy bodies and Lewy neurites. Although HSPGs clearly colocalized with senile plaques, we were unable to identify HSPGs or GAGs in Lewy bodies and Lewy neurites and therefore concluded that it is likely that α-synuclein fibrillization and stabilization occurs independently of the presence of HSPGs or GAGs. Show more
Keywords: lewy body, lewy neurites, parkinson's disease, heparan sulfate proteoglycan, glycosaminoglycan
DOI: 10.3233/JAD-2004-6502
Citation: Journal of Alzheimer's Disease, vol. 6, no. 5, pp. 469-474, 2004
Authors: Menéndez, Manuel
Article Type: Research Article
Abstract: The presenilins are two closely related genes which implication in familial Alzheimer's disease (FAD) is well known. Presenilin 1 gene (PS1) mutations cause heterogeneous disorders and a bibliographical review of atypical PS1-FAD cases allows us to describe a great diversity of neuropathological and clinical variations and conclude that most of them do not strongly depend on the genetic location of the mutation so other genetic or epigenetic factors may be involved.
Keywords: Alzheimer's disease, presenilin, phenotype, pathology, mutation, heterogeneity
DOI: 10.3233/JAD-2004-6503
Citation: Journal of Alzheimer's Disease, vol. 6, no. 5, pp. 475-482, 2004
Authors: Hara, Hideo | Monsonego, Alon | Yuasa, Katsutoshi | Adachi, Kayo | Xiao, Xiao | Takeda, Shin'ichi | Takahashi, Keikichi | Weiner, Howard L. | Tabira, Takeshi
Article Type: Research Article
Abstract: A new oral vaccine for Alzheimer's disease was developed using recombinant adeno-associated virus vector carrying Aβ cDNA (AAV/Aβ). Oral administration of the vaccine without adjuvant induced the expression and secretion of Aβ1–43 or Aβ1–21 in the epithelial cell layer of the intestine in amyloid precursor protein transgenic mice. Serum antibody levels were elevated for more than six months, while T cell proliferative responses to Aβ was not detected. Brain Aβ burden was significantly decreased compared to the control without inflammatory changes. This oral AAV/Aβ vaccine seems to be promising for prevention and treatment of Alzheimer's disease.
DOI: 10.3233/JAD-2004-6504
Citation: Journal of Alzheimer's Disease, vol. 6, no. 5, pp. 483-488, 2004
Authors: Robertson, Laura A. | Moya, Kenneth L. | Breen, Kieran C.
Article Type: Research Article
Abstract: Single O-linked N-acetylglucosamine (O-GlcNAc) sugar residues can compete with phosphate groups to occupy specific sites on certain nuclear and cytosolic proteins. Here we show that inhibiting cellular kinase activities resulted in changes in protein O-glycosylation levels in heat-stable cytoskeletal protein fractions derived from primary neuronal cells. As increased phosphorylation of the microtubule-associated protein tau is one of the pathological hallmarks of Alzheimer's disease and glycosylation may play an influential role in this process. We observed a significant decrease in the protein O-GlcNAc glycosylation of a tau-enriched cytoskeletal fraction generated from AD post-mortem brain samples as compared with control, suggesting an …inverse relationship between the two post-translational modifications. Finally, cells transfected with the cDNA coding for O-GlcNAc transferase (OGT) displayed altered tau phosphorylation patterns as compared with control cells, suggesting that changes in tau glycosylation may influence its phosphorylation state. The specificity of the changes in the phosphorylation of individual amino acid residues provides evidence for a targeted O-glycosylation of tau. Show more
Keywords: glycosylation, phosphorylation, tau, Alzheimer's, Fronto-temporal dementia, neurofibrillary tangles
DOI: 10.3233/JAD-2004-6505
Citation: Journal of Alzheimer's Disease, vol. 6, no. 5, pp. 489-495, 2004
Authors: Ben-Avi, Liat | Durst, Ronen | Shpitzen, Shoshi | Leitersdorf, Eran | Meiner, Vardiella
Article Type: Research Article
Abstract: Apolipoprotein E (apo E) is an essential constituent of several plasma lipoproteins, and plays an important role in lipoprotein metabolism. The apo E gene exhibits two common functional polymorphisms, producing 3 isoforms known to be associated with the risks of developing cardiovascular disease and susceptibility to Alzheimer's disease. Numerous different methods have been established for determining the three apo E isoforms, yet there are disadvantages and ambiguities associated with all of them. We used a method adapted for multiplex automated primer extension analysis by improving a commercially available protocol (SNaPshot™) and simultaneously typing apo E single nucleotide polymorphisms (SNPs) …encoding for isoforms at codon 112 and 158. This protocol relies on the extension with fluorescent dideoxyNTPs of a primer that ends one nucleotide 5' of a given SNP (minisequencing). Improvement of the method is achieved by incorporating into the minisequencing reaction two pooled primers corresponding to both apo E SNPs followed by analysis on an ABI PRISM 310 DNA sequencer. We found full concordance with genotypes determined using universal heteroduplex. This method is readily available for many laboratories and is a simple, unequivocal easy to use technique suitable for large amount of clinical samples that may provide a significant improvement over previously reported methods for apo E genotyping. Show more
Keywords: Apolipoprotein E, genotyping, single nucleotide polymorphism, Alzheimer's disease, coronary artery disease
DOI: 10.3233/JAD-2004-6506
Citation: Journal of Alzheimer's Disease, vol. 6, no. 5, pp. 497-501, 2004
Authors: Ala, Thomas A. | Doss, Robert C. | Sullivan, Christopher J.
Article Type: Research Article
Abstract: A 70-year-old man presented to us in 1994 with a three-year history of worsening dementia. With the exceptions of a Mini-Mental State exam score of 20 and an inability to tandem walk, his physical and neurological examinations were normal. His past medical history revealed that in 1992 he had been evaluated at another institution for memory impairment and bifrontal headaches. A spinal tap had been done in 1992 showing elevated protein, reduced glucose, and a pleocytosis; his CSF fungal culture and cryptococcal antigen test were negative. He subsequently was lost to follow-up, and although his headaches had resolved, his mental …status had continued to worsen. In 1994 his CSF cryptococcal antigen was positive, and his CSF fungal culture grew C. neoformans. He gradually improved with treatment for cryptococcal meningitis (CM). With the exception of mild memory impairment, in 2003 he and his family thought that his mental status had returned to normal. This case emphasizes that: 1) CM should always be kept in the differential diagnosis of dementia; 2) CM may be extremely insidious and difficult to diagnose; and 3) if one is to rule out unequivocally all possible reversible causes of dementia, one should perform a spinal tap. Show more
Keywords: dementia, reversibility, Alzheimer's disease, cryptococcal meningitis, CNS infection, diagnosis, differential diagnosis
DOI: 10.3233/JAD-2004-6507
Citation: Journal of Alzheimer's Disease, vol. 6, no. 5, pp. 503-508, 2004
Authors: Costa, David A. | Nilsson, Lars N.G. | Bales, Kelly R. | Paul, Steven M. | Potter, Huntington
Article Type: Research Article
Abstract: To determine the role of apolipoprotein E (apoE) in the deposition of different forms of Alzheimer amyloid deposit, we studied mice expressing both mutant human amyloid β-protein precursor (AβPP) and presenilin 1 (PS1) that, in addition, were either normal or knocked-out for apoE. By 7 months of age, extensive deposits of amorphous amyloid β (Aβ) had developed equally in both lines, indicating that, when present in high amounts, Aβ alone is sufficient for such deposition to occur. In contrast, filamentous, thioflavine S-positive amyloid deposition in AβPP/PS mice was catalyzed at least 3000 fold by apoE. Electron micrographs further illustrated the …filamentous nature of Aβ deposits in mice expressing apoE. These and other behavior data indicate that the primary function of apoE in Alzheimer's disease is to promote the polymerization of Aβ into mature, beta pleated sheet filaments, a process that is necessary for inducing cognitive decline. Thus, preventing apoE from binding to Aβ may prove to be an effective means of therapeutic intervention. Show more
Keywords: Alzheimer's disease, amyloid β, amyloid β-protein precursor apolipoprotein E, transgenic mouse model
DOI: 10.3233/JAD-2004-6508
Citation: Journal of Alzheimer's Disease, vol. 6, no. 5, pp. 509-514, 2004
Authors: Boyd-Kimball, Debra | Sultana, Rukhsana | Mohmmad-Abdul, Hafiz | Butterfield, D. Allan
Article Type: Research Article
Abstract: Alzheimer's disease is a neurodegenerative disorder associated with aging and cognitive decline. Amyloid beta peptide (1–42) [Aβ(1–42)] is a primary constituent of senile plaques – a hallmark of Alzheimer's disease – and has been implicated in the pathogenesis of the disease. Previous studies have shown that methionine residue 35 of β(1–42) may play a critical role in Aβ(1–42)-mediated oxidative stress and neurotoxicity. Several additional mechanisms of neurotoxicity have been proposed, including the role of Cu(II) binding and reduction to produce hydrogen peroxide and the role of peptide aggregation. It has been reported that rodent Aβ is less likely to …form larger β-sheet structures, and consequently, large aggregates. As a consequence of the lack of deposition of the peptide in rodent brain, rodent Aβ has been proposed to be non-toxic. Additionally, the sequence of the rodent variety of Aβ(1–42) contains three amino acid substitutions compared to the human sequence. These substitutions include the shift of arginine 5, trysosine 10, and histidine 13 to glycine, phenylalanine, and arginine, respectively. This shift in sequence within the Cu(II) binding region of the peptide results in a decrease in the ability of the rodent Aβ peptide to reduce Cu(II) to Cu(I) compared to the human Aβ peptide. As a result of the effect of the amino acid variations on the ability of the rodent peptide to reduce Cu(II) to Cu(I) compared to the human peptide, the rodent β has been proposed to lack oxidative stress properties. In this study, the oxidative stress and neurotoxic properties of rodent β(1–42) [Aβ(1–42)Rat] were evaluated and compared to those of human Aβ(1–42). Both human Aβ(1–42) and β(1–42)Rat were found to have a significant effect on neuronal DNA fragmentation, loss of neuritic networks, and cell viability. β(1–42) Rat was found to cause a significant increase in both protein oxidation and lipid peroxidation, similar to Aβ(1–42), both of which were inhibited by the lipid-soluble, chain breaking antioxidant vitamin E, suggesting that reactive oxygen species play a role in the Aβ-mediated toxicity. Taken together, these results suggest that Cu(II) reduction may not play a critical role inβ(1–42)Rat-induced oxidative stress, and that the oxidative stress exhibited by this peptide may be a consequence of the presence of methionine 35, similar to the findings associated with the native human β(1–42) peptide. Show more
Keywords: Alzheimer's disease, amyloid β-peptide, rodent amyloid β-peptide, oxidative stress
DOI: 10.3233/JAD-2004-6509
Citation: Journal of Alzheimer's Disease, vol. 6, no. 5, pp. 515-525, 2004
Authors: Luo, LuGuang | Stopa, Edward G.
Article Type: Research Article
Abstract: Depletion of thyrotropin releasing hormone (TRH) gene expression resulted in augmented tau and glycosynthetase kinase-3β (GSK-3β), in contrast, TRH administration resulted in decreases of 75% in GSK-3β and 90% in Tau phosphorylation in cultured rat hippocampal neurons. To further study TRH regulation of tau phosphorylation, immunoblotting was used to explore G-protein coupled TRH receptor activation of the phosphokinase C (PKC) and phosphokinase A (PKA) signaling pathways. TRH was found to rapidly activate PKA (2.5 fold in 10 min) while it suppressed PKC (levels decreased by 85% vs. control) in hippocampal neurons. This process was also discovered to be a cell …type-specific response, as TRH activated PKC in only hypothalamic neurons. Further investigation revealed that the Src inhibitor Protein Phosphatase 2 (PP2, 50 uM) could block TRH inhibition of PKC, GSK-3β, and tau phosphorylation with no effects on PKA. In addition, the PKC inhibitor GF109203 Bis (10 uM) was also able to suppress TRH inhibition of GSK-3β, leading to increased GSK-3 β activity. Independent of these effects, inhibition of PKA by H89 (10 uM) significantly blocked TRH inhibition of GSK-3 β. These data suggests that both PKA and PKC are independently crucial to TRH's effects on GSK-3 β, and support the roles of two distinct pathways involving suppression of PKC via the Src kinase and activation of PKA in mediating TRH effects on GSK-3 β and tau. These dual signaling pathways between TRH and tau may provide mechanisms for the precise regulation of tau phosphorylation and dephosphorylation in neurons. Show more
Keywords: TRH, Tau, PKA, PKC, Src, signal transduction, hippocampal neurons
DOI: 10.3233/JAD-2004-6510
Citation: Journal of Alzheimer's Disease, vol. 6, no. 5, pp. 527-536, 2004
Article Type: Discussion
DOI: 10.3233/JAD-2004-6511
Citation: Journal of Alzheimer's Disease, vol. 6, no. 5, pp. 537-545, 2004
Authors: Dobrota, Dusan | Lyness, Scott A. | Aliev, Gjumrakch
Article Type: Research Article
DOI: 10.3233/JAD-2004-6512
Citation: Journal of Alzheimer's Disease, vol. 6, no. 5, pp. 547-568, 2004
Article Type: Book Review
DOI: 10.3233/JAD-2004-6513
Citation: Journal of Alzheimer's Disease, vol. 6, no. 5, pp. 569-569, 2004
Article Type: Other
DOI: 10.3233/JAD-2004-6514
Citation: Journal of Alzheimer's Disease, vol. 6, no. 5, pp. 571-571, 2004
Article Type: Announcement
DOI: 10.3233/JAD-2004-6515
Citation: Journal of Alzheimer's Disease, vol. 6, no. 5, pp. 573-575, 2004
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]